

Journal section: *Oral Medicine and Pathology*  
 Publication Types: *Research*

doi:10.4317/medoral.20368  
<http://dx.doi.org/doi:10.4317/medoral.20368>

## Serum vitamin D levels of patients with oral squamous cell carcinoma (OSCC) and expression of vitamin D receptor in oral precancerous lesions and OSCC

Martin Grimm <sup>1</sup>, Marcel Cetindis <sup>1</sup>, Thorsten Biegner <sup>2</sup>, Max Lehman <sup>1</sup>, Adelheid Munz <sup>1</sup>, Peter Teriete <sup>3</sup>, Siegmar Reinert <sup>1</sup>

<sup>1</sup> Department of Oral and Maxillofacial Surgery, University Hospital Tuebingen, Osianderstrasse 2-8, 72076 Tuebingen, Germany

<sup>2</sup> Department of Pathology, University Hospital Tuebingen, Liebermeisterstrasse 8, 72076 Tuebingen, Germany

<sup>3</sup> Cancer Research Center, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA

### Correspondence:

Department of Oral and Maxillofacial Surgery  
 University Hospital Tuebingen  
 Osianderstrasse 2-8, 72076  
 Tuebingen, Germany  
[dr.dr.martingrimm@googlemail.com](mailto:dr.dr.martingrimm@googlemail.com)

Grimm M, Cetindis M, Biegner T, Lehman M, Munz A, Teriete P, Reinert S. Serum vitamin D levels of patients with oral squamous cell carcinoma (OSCC) and expression of vitamin D receptor in oral precancerous lesions and OSCC. *Med Oral Patol Oral Cir Bucal*. 2015 Mar 1;20 (2):e188-95.  
<http://www.medicinaoral.com/medoralfree01/v20i2/medoralv20i2p188.pdf>

Received: 09/09/2014  
 Accepted: 07/11/2014

Article Number: 20368 <http://www.medicinaoral.com/>  
 © Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946  
 eMail: [medicina@medicinaoral.com](mailto:medicina@medicinaoral.com)  
**Indexed in:**  
 Science Citation Index Expanded  
 Journal Citation Reports  
 Index Medicus, MEDLINE, PubMed  
 Scopus, Embase and Emcare  
 Indice Médico Español

### Abstract

**Background:** Resistance to programmed cell death (apoptosis) is a crucial factor for the carcinogenesis of oral squamous cell carcinoma (OSCC). Vitamin D (calcitriol) may overcome apoptosis resistance in tumor cells of OSCC. Vitamin D receptor (VDR) expression in oral precancerous lesions of OSCC has not been analyzed and serum vitamin D level seems to be a predictor of cancer development.

**Material and Methods:** Expression of VDR was analyzed in normal oral mucosa (n=5), oral precursor lesions (simple hyperplasia, n=11; squamous intraepithelial neoplasia, SIN I-III, n=35), and OSCC specimen (n=42) by immunohistochemistry (IHC). Moreover, serum vitamin D levels were measured by 25(OH)D3 (calcidiol) in patients with OSCC (n=42) and correlated with IHC results.

**Results:** Expression of VDR was significantly increased in precancerous and OSCC compared with normal tissue. Compared with SIN I-III lesions VDR expression significantly decreased in OSCC. Severe vitamin D deficiency was detected in our OSCC patient cohort but there was no significant correlation analyzed between serum vitamin D levels and corresponding immunohistochemically detected VDR expression in OSCC.

**Conclusions:** Our survey provides the first evidence of VDR expression in precancerous lesions of OSCC. Apoptosis induction of VDR+ cells in oral precancerous lesions and OSCC by natural vitamin D or synthetic vitamin D compounds could be useful for chemoprevention. Moreover, systemically and/or locally applied, these compounds may act as sensitizers for apoptosis mediated by radio-, and chemotherapy treatment in OSCC.

**Key words:** *Oral cancer, oral precancer, lichen planus, leukoplakia, apoptosis, serum 25(OH)D3, vitamin D receptor, chemoprevention, multistep carcinogenesis.*

## Introduction

The development of oral squamous cell carcinoma (OSCC) is a multistep process that influence key cellular pathways involved in tumor development and growth. A diversity of endogenous and exogenous stimuli is leading to a complex series of molecular changes participating in cancer development (1,2). The subsequent rise of malignant tumors from a single transformed cell and the development through detectable precancerous stages is described by the model of multistep carcinogenesis (3). This fact depicts the need for continued efforts to discover new biomarkers for the early OSCC diagnosis and therapy as well as for the improved understanding of disease pathogenesis as a first step towards improving treatment. The pace of clinical translation in the field of molecular translational oncology has accelerated in the last few years. Analyzing the mechanistic basis of the multistep process potentially allows the development of molecular tools to manipulate oral carcinogenesis, which is relevant to the practicing oncologist.

OSCC is a major cause of morbidity and mortality worldwide with low response to chemotherapy and basic resistance to most standard anticancer drugs (4,5). The process of programmed cell death (apoptosis) that may occur in multicellular organisms is a genetically regulated cell death involved in the deletion of cells in normal as well as malignant tissues (6). Resistance to apoptosis (7) is known as a crucial factor for the carcinogenesis of OSCC, which is associated with tumor recurrence as well as radio-, and chemotherapy resistance (8,9). Therefore, overcoming apoptosis resistance is a major aim in the treatment of OSCC.

In a number of cell types, the antineoplastic activity of 1,25-dihydroxyvitamin D<sub>3</sub> (1,25-(OH)<sub>2</sub>D<sub>3</sub>, calcitriol) contributes to the induction of apoptosis, inhibition of invasiveness, and angiogenesis (10,11). The antineoplastic activity of 1,25-(OH)<sub>2</sub>D<sub>3</sub> was shown in-vitro and in-vivo in a wide variety of malignancies including head and neck cancer (12-18) and specifically OSCC (19-21). Moreover, the effectiveness of cytostatic chemotherapy to induce apoptosis in OSCC cells is enhanced by calcitriol (21).

In general, the measurement of serum calcidiol is a better predictor of cancer development than calcitriol (1,25-(OH)<sub>2</sub>D<sub>3</sub>) (22,23). Studying serum vitamin D level and its corresponding vitamin D receptor (VDR) seems to be reasonable for guiding supportive treatment of patients with precancerous lesions and OSCC.

Recently, we have demonstrated low VDR expression as an adverse prognostic factor for the survival of patients with OSCC (11). However, the expression of VDR in different precancerous lesions has not been described yet. Therefore, the purpose of this study was to investigate VDR expression in precancerous lesions. Moreover, serum vitamin D levels (calcidiol) were measured

and correlated with tissue-related VDR expression in OSCC patients.

## Material and Methods

### - Patients and Tumor Specimen

The records of healthy individuals (normal oral mucosal tissues, n=5), patients with oral precursor lesions (simple hyperplasia, n=11; squamous intraepithelial neoplasia SIN I, n=5; SIN II, n=9; SIN III, severe dysplasia, n=10; SIN III, carcinoma in situ, n=11), and patients with invasive OSCC (n=42, Table 1) were retrospectively assessed from January 2009 to December 2013. Out of these 42 precursor lesions, 4 specimens were clinically and histopathologically classified as oral lichen planus and 38 specimens presented as leukoplakia. The diagnosis of normal oral mucosal tissues, precursor lesions, and invasive squamous cell carcinoma was confirmed by the department of Pathology, University Hospital Tuebingen. The material was archival formalin-fixed,

**Table 1.** Clinicopathological characteristics of 42 patients with OSCC.

Characteristics	Number of Patients Total n=42
<b>Gender</b>	
Male	24
Female	18
<b>Histological Grading</b>	
G1	7
G2	25
G3	9
G4	1
<b>Depth of invasion</b>	
pT1	10
pT2	11
pT3	5
pT4	16
<b>Cervical lymph node metastasis</b>	
pN0	26
pN1	4
pN2	10
pN3	2
<b>UICC stage</b>	
UICC I	8
UICC II	4
UICC III	6
UICC IV	24
<b>Distant metastasis</b>	
yes	2
no	40
<b>Site distribution of OSCC</b>	
Tongue	10
Floor of the mouth	20
Palate	5
Buccal mucosa	1
Alveolar ridge	6

paraffin-embedded tissue from routine histopathological work-ups. The material has been stored with permission of the local ethics committee of the University Hospital Tuebingen (approval number: 562-2013BO2), after informed consent obtained from the patients prior to surgical resection. Tumor blocks of paraffin-embedded tissue were selected by experienced pathologists, evaluating the routine H&E stained sections. Sections from all available tissues underwent histopathological assessment, blinded to the prior histopathology report. Serial tissue sections (2  $\mu$ m thickness) were cut from formalin-fixed paraffin-embedded (FFPE) blocks on a microtome and mounted from warm water onto adhesive microscope slides. First, we assessed H&E sections from each tissue section to differentiate between normal tissue, precursor lesions, tumor cell areas, stromal areas, and infiltrating immune cells. Oral precursor lesions were classified according to WHO criteria (3). Tumor staging was performed according to the 7th edition of the TNM staging system by the UICC/ AJCC of 2010. Grading of OSCC was defined according to WHO criteria.

- Staining procedure and quantification of immunohistochemistry

We stained for VDR (LifeSpan Biosciences, Eching, Germany, rabbit anti-human VDR pAb, LS-B2976, dilution: 1:100, (11) in tissue sections. Staining was performed on serial sections of 2 $\mu$ m thickness, which were deparaffinized in xylene and ethanol and rehydrated in water. Heat induced epitope retrieval (HIER) was performed with citrate buffer pH 6.0 (Dako, Hamburg, Germany). Endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide. Endogenous biotin activity was blocked using the avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA, USA). After incubation with the primary or control antibody the Dako LSAB2 peroxidase System (Dako, Hamburg) was used. Slides were subsequently incubated for 5 minutes in DAB (3,3'-diaminobenzidine, Biogenex) counterstained with haemalaun and mounted with Glycergel (Dako).

Five representative high power fields (1 HPF = 0.237 mm<sup>2</sup>, original magnification: x200-fold) were analyzed for VDR expression in normal tissue, oral precursor lesions, tumor tissue and averaged, respectively. The extent of the staining, defined as the percentage of positive staining areas of tumor cells in relation to the whole tissue area, was semi-quantitatively scored on a scale of 0 to 3 as the following: 0, <10%; 1, 10–30%; 2, 30–60%; 3, >60%. The intensities of the signals were scored as 1+, 2+, and 3+. Then, a combined score (0–9) for each specimen was calculated by multiplying the values of these two categories (24). Cases were classified as negative, 0 points, positive, 1-9 points. Two observers blinded to the diagnosis performed scoring on identical sections marked by circling with a water-resistant pencil and fi-

nally with diamond-tipped pencil on the opposite side of the microscopic slide. Pictures were analyzed using a Canon camera (Krefeld, Germany). The photographed images were imported into the Microsoft Office Picture Manager.

- Measurement of serum 25(OH)D3 (Calcidiol) concentrations in patients with OSCC

From patients with invasive OSCC (n=42), in each case, serum samples were obtained in the preoperative period and stored at -80°C until 25(OH)D3 was measured. Serum 25(OH)D3 levels were measured twice by radioimmunoassay at Biovis laboratory (Limburg-Offheim, Germany). History of cancer patients gave no indication for severe kidney or hepatic dysfunction. Serum levels >35 ng/ml, 25-35 ng/ml, 12.5-25 ng/ml and <12.5 ng/ml were considered as normal, mild, moderate and severe vitamin D deficiency, respectively (25).

- Statistical analysis

Statistical analysis was performed with MedCalc Software, Version 13.1.1 (Mariakerke, Belgium). Data were analyzed using the non-parametric Mann-Whitney U Test or Kruskal-Wallis test when more than 2 groups were compared. Correlation analysis of immunohistochemically detected VDR expression with serum 25(OH)D3 was performed by the non-parametric Kendall's tau ( $\tau$ ) coefficient. All p-values presented were 2-sided and  $p < 0.05$  was considered statistically significant.

## Results


- VDR expression in normal mucosa, oral precursor lesions and OSCC

VDR was found expressed in all tissue types (Fig. 1 and 2), normal oral mucosa (n=5/5), oral precursor lesions (simple hyperplasia, n=11/11; squamous intraepithelial neoplasia, SIN I-III, n=35/35), and OSCC specimen (n=42/42). In comparison to normal tissue a significantly ( $p < 0.05$ ) increased expression of VDR (Fig. 1 and 2) was observed in tumor cells of OSCC. Compared with SIN I-III VDR expression was significantly decreased in OSCC (Fig. 1 and 2).

- Serum 25(OH)D3 (calcidiol) values in patients with OSCC and correlation with corresponding immunohistochemically detected VDR expression

No patient (n=0/42, 0%) showed normal (>35 ng/ml) serum vitamin D levels or mild (25-35 ng/ml) vitamin D deficiency. In 16 out of 42 patients (n=16/42, 38%) moderate (12.5-25 ng/ml) vitamin D deficiency was analyzed and in 26 out of 42 patients (n=26/42, 62%) severe (<12.5 ng/ml) vitamin D deficiency was detected. The mean serum vitamin D level was measured at 12.2 ng/ml (range: 4.0-19.9 ng/ml) in all OSCC patients.

There was no significant correlation found between serum 25(OH)D3 values and corresponding immunohistochemically detected VDR expression in patients with OSCC (n=42):  $\tau = 0.114$ ,  $p = 0.2916$ .




**Fig. 1.** Immunohistochemical staining of VDR in OSCC. Immunohistochemical staining shows representative images of VDR in N.T. (A), SIN (B), and OSCC (C). Brown chromogen color (3,3'-Diaminobenzidine) indicates positive staining, the blue color shows the nuclear counterstaining by hematoxylin. The square box demonstrates the area of interest (original magnification: x100-fold, left panel) which is also shown in larger magnification (x200-fold, right panel). VDR, vitamin D receptor; SIN, squamous intraepithelial neoplasia; N.T., normal tissue.

## Discussion

In our survey, we analyzed for the first time VDR expression in different precancerous lesions of OSCC. In patients with OSCC corresponding vitamin D levels were investigated and correlated with immunohistochemical VDR expression. We analyzed increased expression of VDR in OSCC compared with normal oral mucosa. However, compared with SIN I-III VDR expression was significantly decreased in OSCC.

To explain tumor heterogeneity and inherent differences of tumor-regenerating capacity two cancer models are described (26). The clonal selection model of multistep carcinogenesis describes that a random solitary cell undergoes malignant transformation, accumulates multiple mutations and subsequently acquires a survival advantage, which leads to clonal selection (27,28). In contrast, the cancer stem cell (CSC) hypothesis hypothesis regards malignant transformation as a process, occurring in a subset of normal stem cells with pluripo-

tent properties, which underlie deregulation of self-renewal pathways (29,30). Although VDR expression has not been described as a classical CSC marker, putative CSC of the breast (31,32) and OSCC (11) express this receptor. CSCs themselves may undergo clonal evolution and therefore, both models are not mutually exclusive (33,34). Our results of decreased VDR expression in OSCC compared with SIN lesions can be explained with the clonal selection model of carcinogenesis, which proposes that there is a subsequent clonal selection of cancer cells or putative CSC during carcinogenesis (26, 32,35). These CSC are resistant to standard adjuvant therapeutic approaches. Enhancing apoptosis in precursor and tumor cells is a key event for cancer therapy and chemoprevention (36). In this connection, natural vitamin D or synthetic vitamin D compounds (10,37) have been demonstrated for induction of apoptosis and play an emerging role in cancer therapy. Several studies have suggested a link between low serum vitamin D levels



**B**

Factor	n	Different (p < 0.05) from factor nr
(1) N.T.	5	(2)(3)(4)(5)(6)(7)
(2) Hyperplasia	11	(1)(3)(4)(7)
(3) SIN I	5	(1)(2)(5)(6)(7)
(4) SIN II	9	(1)(2)(5)(6)(7)
(5) SIN III (sev. dysplasia)	10	(1)(3)(4)(7)
(6) SIN III (CIS)	11	(1)(3)(4)
(7) OSCC	42	(1)(2)(3)(4)(5)

**Fig. 2.** Immunohistochemical analysis of VDR in normal oral mucosal tissue, oral precursor lesions - hyperplasia, SIN, and invasive OSCC. In comparison with normal tissue a significantly increased expression of VDR is observed in hyperplasia, SIN I - SIN III lesions, and OSCC (p < 0.05, Kruskal-Wallis Test; A and B). In comparison with SIN I, SIN II, and SIN III (sev. dysplasia) a significantly decreased expression of VDR is observed in OSCC. VDR expression is significantly decreased in OSCC compared with SIN I-III (p < 0.0001, Mann-Whitney U Test). Analysis refers to averaged scores. Red line indicates VDR expression results in carcinogenesis. Grey lines show 95% confidence intervals. Analysis of significant statistically different single values is indicated in the table below (B). SIN III is subdivided in severe dysplasia and carcinoma in situ (CIS). VDR, vitamin D receptor; SIN, squamous intraepithelial neoplasia; N.T., normal tissue.

and an increased risk of cancer (38,39), overall with the strongest evidence for breast and colorectal cancer. Moreover, higher vitamin D intake is linked with a lower risk for breast cancer (40). Recent data indicate that the safe upper intake level for Calcitriol is 10,000 IU/d (41), which is substantially more potent than ergocalciferol (vitamin D2). Authors assume that induction of apoptosis in VDR+ precancerous lesions (e.g. leukoplakia

or oral lichen planus) and tumors by vitamin D could be useful for chemoprevention or may act as sensitizers for apoptosis in the treatment of OSCC (37). This hypothesis has to be evaluated in clinical studies. In a Murine Model of Cutaneous Squamous Cell Carcinoma oral calcitriol supplementation enhanced Photodynamic therapy-induced tumor cell death (42). Therefore, topical and/or systemically applied vitamin d (or in

combination with vitamin A derivatives (21) may be considered as a possible new, non-toxic, adjuvant cancer therapy, which can be easily introduced into the classic protocols of clinical cancer therapy without any supplementary risk for VDR+ patients. With specific regard to the hypothesis of the field cancerization (43,44) systemically applied vitamin D seems very meaningful as the tissue of the gastrointestinal tract is exposed to the two main exogenous carcinogenic factors, tobacco and alcohol (45). If the carcinogenic stimuli continue, second metachronous tumors in related sites may occur (45).

From our results, we don't know whether increased VDR expression in oral precancerous or OSCCs exhibits a functionally inactivating mutation and this may be due to a feedback loop coupled with an expression by the tumour cells of a defective VDR (46). In different cell types, Calcitriol has been shown to enhance VDR expression on gene and protein level in vitro (47,48). It has been assumed that the increase of VDR expression following calcitriol administration is due to an increased receptor protein lifetime (48) and/or elevated transcription of VDR genes (49). The study by Lehmann *et al.* indicated that human keratinocytes may have the capacity to hydroxylate vitamin D at the C-1 and C-25 positions (50). Keratinocytes could be able to synthesize the biologically active calcitriol, therefore. However, we don't know if oral precancerous or OSCCs are able to synthesize calcitriol as well. It can be speculated whether the increased content of VDR on the mRNA and protein levels that we have shown in this study is due to an increased formation of calcitriol in these tumour cells. Moreover, inflammatory peptides/cytokines expressed by tumour-infiltrating leucocytes and oral precancerous/tumour cells may upregulate VDR expression in adjacent cells (51).

Overall, the vitamin D status may be associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract (52). Evidence from the literature suggests the relationship between serum calcidiol concentration and cancer prevention as an optimal level of 80 nmol/L (~32 ng/ml) (22,41). Based on the literature review on vitamin D status in the Central Europe (CE) populations, it can be concluded that 25-OH vitamin D levels are on average below the 30 ng/mL level. In wintertime 25-OH vitamin D values of the CE population are close to 21-23 ng/mL for all studied age groups, with a significant increase of 25-OH vitamin D in August reaching 42 ng/mL for those aged 0-9 years, but only 21 ng/mL for the elderly aged 80-89 years (53). Focusing on head and neck squamous cell carcinoma (HNSCC), a previous study by Arem *et al.* (54) analyzed a median serum 25-OH vitamin D level at 31 nmol/L (~12 ng/ml) without association of oropharynx cancer in Finnish men (includ-

ing n=131 patients with OSCC). Our results are well in line with the results by Arem *et al.* (54) demonstrating a severe vitamin D deficiency in our patient cohort (mean serum vitamin D level 12.2 ng/ml), which is lower compared with 'normal' CE population as described by Pludowski *et al.* above (53).

However, a previous published study by Yuan *et al.* (55) strongly supports a crucial role for vitamin D signaling in oral keratinocyte pathophysiology in-vitro and in-vivo but vitamin D deficiency alone seems to be insufficient to alter oral epithelial homeostasis and provoke carcinogenesis. Afzal *et al.* (56) demonstrated a low plasma 25-hydroxyvitamin D level with increased risk of tobacco-related cancer including HNSCC. In this context vitamin D may conversely modify the carcinogenicity of tobacco smoke chemicals. Authors hypothesize that especially smokers may benefit from Vitamin D intake as more than 80% of OSCC are associated with tobacco abuse.

Oral keratinocytes are able to synthesize the biologically active calcitriol. The steroid hormone responsiveness is directly proportional to the number of corresponding receptors (47). Therefore, we performed correlation analysis of serum vitamin D levels and the corresponding VDR in the tumor tissue of OSCC patients but the data did not show any significant correlation. This can be explained as many cytokines and inflammatory peptides excreted by tumour-infiltrating leucocytes as well as tumour cells may influence VDR expression (51).

As suggested for multistep carcinogenesis (2) it is unclear based on the actual literature whether vitamin D can be standardized effective for chemoprevention in the treatment of precursor lesions or OSCC development but it provides a clear rationale for further studies in the carcinogenesis of OSCC.

## Conclusions

Our survey provides the first evidence of VDR expression in OSCC. Apoptosis induction of VDR+ cells in oral precancerous lesions and OSCC by natural vitamin D or synthetic vitamin D compounds (10) could be useful for chemoprevention. Moreover, systemically and/or locally applied, these compounds may act as sensitizers for apoptosis mediated by radio-, and chemotherapy treatment in OSCC.

## References

1. Choudhary SK, Chaudhary M, Gadbail AR, Sharma A, Tekade S. Oxidative and antioxidative mechanisms in oral cancer and precancer: a review. *Oral Oncol.* 2014;50:10-8.
2. Tanaka T, Tanaka M, Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: a review. *Patholog Res Int.* 2011;2011:431246.
3. Driemel O, Hertel K, Reichert TE, Kosmehl H. Current classification of precursor lesions of oral squamous cell carcinoma principles of the WHO classification 2005. *Mund Kiefer Gesichtschir.* 2006;10:89-93.



4. Grimm M. Prognostic value of clinicopathological parameters and outcome in 484 patients with oral squamous cell carcinoma: microvascular invasion (V+) is an independent prognostic factor for OSCC. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.* 2012;14:870-80.
5. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible factors in OSCC. *Cancer letters.* 2011;313:1-8.
6. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. *Cell Prolif.* 2012;45:487-98.
7. Sinha N, Mukhopadhyay S, Das DN, Panda PK, Bhutia SK. Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. *Oral Oncol.* 2013;49:854-62.
8. Grimm M, Schmitt S, Teriete P, Biegner T, Stenzl A, Hennenlotter J, et al. A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. *BMC Cancer.* 2013;13:569.
9. Richard V, Sebastian P, Nair MG, Nair SN, Malieckal TT, Santhosh Kumar TR, et al. Multiple drug resistant, tumorigenic stem-like cells in oral cancer. *Cancer Lett.* 2013;338:300-16.
10. Nair R, Maseeh A. Vitamin D: The "sunshine" vitamin. *J Pharmacol Pharmacother.* 2012;3:118-26.
11. Grimm M, Alexander D, Munz A, Hoffmann J, Reinert S. Is 1,25-dihydroxyvitamin D3 receptor expression a potential Achilles' heel of CD44+ oral squamous cell carcinoma cells?. *Target Oncol.* 2013;8:189-201.
12. Kornfehl J, Formanek M, Temmel A, Knerer B, Willheim M. Antiproliferative effects of the biologically active metabolite of vitamin D3 (1,25 [OH]2 D3) on head and neck squamous cell carcinoma cell lines. *European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies.* 1996;253:341-4.
13. Kulbersh JS, Day TA, Gillespie MB, Young MR. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. *Otolaryngology-head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery.* 2009;140:235-40.
14. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. *Int J Cancer.* 1997;74:69-74.
15. Lu L, Qiu J, Liu S, Luo W. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. *Molecular cancer therapeutics.* 2008;7:1268-74.
16. Hager G, Kornfehl J, Knerer B, Weigel G, Formanek M. Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. *Acta oto-laryngologica.* 2004;124:90-6.
17. Satake K, Takagi E, Ishii A, Kato Y, Imagawa Y, Kimura Y, et al. Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma. *Auris Nasus Larynx.* 2003;30:403-12.
18. Prudencio J, Akutsu N, Benlimame N, Wang T, Bastien Y, Lin R, et al. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. *Journal of the National Cancer Institute.* 2001;93:745-53.
19. Meier JD, Enepekides DJ, Poirier B, Bradley CA, Albala JS, Farwell DG. Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3) to inhibit carcinogenesis in the hamster buccal pouch model. *Archives of otolaryngology--head & neck surgery.* 2007;133:1149-52.
20. Osafi J, Hejazi A, Stutz DD, Keiserman MA, Bergman CJ, Kingsley K. Differential effects of 1,25-dihydroxyvitamin D(3) on oral squamous cell carcinomas in vitro. *J Diet Suppl.* 2014;11:145-54.
21. Dalirsani Z, Farajnia S, Javadzadeh Y, Mehdipour M, Koozegari S. The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. *J Contemp Dent Pract.* 2012;13:345-50.
22. Tuohimaa P, Lou YR. Optimal serum calcidiol concentration for cancer prevention. *Anticancer Res.* 2012;32:373-81.
23. Zerwekh JE. Blood biomarkers of vitamin D status. *Am J Clin Nutr.* 2008;87:1087S-91S.
24. Walker RA. Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I. *Histopathology.* 2006;49:406-10.
25. Alipour S, Hadji M, Hosseini L, Omranipour R, Saberi A, Seifollahi A, et al. Levels of serum 25-hydroxy-vitamin d in benign and malignant breast masses. *Asian Pac J Cancer Prev.* 2014;15:129-32.
26. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer.* 2008;8:755-68.
27. Nowell PC. The clonal evolution of tumor cell populations. *Science.* 1976;194:23-8.
28. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? *Cell Cycle.* 2007;6:2332-8.
29. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med.* 1997;3:730-7.
30. Reya T, Clevers H. Wnt signalling in stem cells and cancer. *Nature.* 2005;434:843-50.
31. So JY, Lee HJ, Smolarek AK, Paul S, Wang CX, Maehr H, et al. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. *Mol Pharmacol.* 2011;79:360-7.
32. Pervin S, Hewison M, Braga M, Tran L, Chun R, Karam A, et al. Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy. *PLoS One.* 2013;8:e53287.
33. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. *Am J Physiol Gastrointest Liver Physiol.* 2008;295:G211-8.
34. Jeon J, Luebeck EG, Moolgavkar SH. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). *Cancer Causes Control.* 2006;17:971-81.
35. von Rahden BH, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C, et al. Lgr5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus? *J Exp Clin Cancer Res.* 2011;30:23.
36. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. *Curr Cancer Drug Targets.* 2009;9:320-40.
37. Sundaram K, Sambandam Y, Tsuruga E, Wagner CL, Reddy SV. 1alpha,25-dihydroxyvitamin D3 modulates CYP2R1 gene expression in human oral squamous cell carcinoma tumor cells. *Horm Cancer.* 2014;5:90-7.
38. Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. *Annu Rev Pharmacol Toxicol.* 2001;41:421-42.
39. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. *Cancer Causes Control.* 2012;23:363-70.
40. Anderson LN, Cotterchio M, Vieth R, Knight JA. Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. *Am J Clin Nutr.* 2010;91:1699-707.
41. Heaney RP. Vitamin D in health and disease. *Clin J Am Soc Nephrol.* 2008;3:1535-41.
42. Anand S, Rollakanti KR, Horst RL, Hasan T, Maytin EV. Combination of oral vitamin D3 with photodynamic therapy enhances tumor cell death in a murine model of cutaneous squamous cell carcinoma. *Photochem Photobiol.* 2014;90:1126-35.
43. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. *Cancer.* 1953;6:963-8.
44. Angadi PV, Savitha JK, Rao SS, Sivaranjini Y. Oral field cancerization: current evidence and future perspectives. *Oral Maxillofac Surg.* 2012;16:171-80.

45. Leon X, del Prado Venegas M, Orus C, Lopez M, Garcia J, Quer M. Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. *Cancer Causes Control*. 2009;20:645-52.
46. Malodobra-Mazur M, Paduch A, Lebioda A, Konopacka M, Rogolinski J, Szymczyk C, et al. VDR gene single nucleotide polymorphisms and their association with risk of oral cavity carcinoma. *Acta Biochim Pol*. 2012;59:627-30.
47. Costa EM, Feldman D. Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. *Endocrinology*. 1987;120:1173-8.
48. Wiese RJ, Uhland-Smith A, Ross TK, Prah J, DeLuca HF. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. *The Journal of biological chemistry*. 1992;267:20082-6.
49. Mangelsdorf DJ, Pike JW, Haussler MR. Avian and mammalian receptors for 1,25-dihydroxyvitamin D3: in vitro translation to characterize size and hormone-dependent regulation. *Proceedings of the National Academy of Sciences of the United States of America*. 1987;84:354-8.
50. Lehmann B. HaCaT cell line as a model system for vitamin D3 metabolism in human skin. *The Journal of investigative dermatology*. 1997;108:78-82.
51. Reichrath J, Rafi L, Muller SM, Mink D, Reitnauer K, Tilgen W, et al. Immunohistochemical analysis of 1,25-dihydroxyvitamin D3 receptor in cervical carcinoma. *Histochem J*. 1998;30:561-7.
52. Gugatschka M, Kiesler K, Obermayer-Pietsch B, Groselj-Strele A, Griesbacher A, Friedrich G. Vitamin D status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract. *Eur Arch Otorhinolaryngol*. 2011;268:1201-4.
53. Pludowski P, Grant WB, Bhattoa HP, Bayer M, Povoroznyuk V, Rudenka E, et al. Vitamin D Status in Central Europe. *Int J Endocrinol*. 2014;2014:589587.
54. Arem H, Weinstein SJ, Horst RL, Virtamo J, Yu K, Albanes D, et al. Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men. *Cancer Epidemiol Biomarkers Prev*. 2011;20:1178-84.
55. Yuan FN, Valiyaparambil J, Woods MC, Tran H, Pant R, Adams JS, et al. Vitamin D signaling regulates oral keratinocyte proliferation in vitro and in vivo. *Int J Oncol*. 2014;44:1625-33.
56. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. *Clin Chem*. 2013;59:771-80.

#### **Competing interests**

The authors have no competing interests.

#### **Authors' contributions**

MG and SR conceived the study, performed the coordination and drafted the manuscript. MC and AM carried out and evaluated immunohistochemistry studies. TB analysed histopathological specimen and evaluated immunohistochemistry studies. ML and PT carried out the data collection and performed the statistical analyses. All authors read and approved the final manuscript.

#### **Acknowledgements**

We thank Julia Grimm for her technical assistance.